dr. shah compares toxicity profiles of ibrutinib and acalabrutinib
Published 6 years ago • 348 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:06
dr. shah on options for ibrutinib-intolerant patients with mcl
-
1:52
dr. shah compares btk inhibitors for mantle cell lymphoma
-
1:00
dr. goy on acalabrutinib versus ibrutinib in mcl
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
1:46
dr. shah discusses sequencing for mcl
-
1:46
dr. o'connor on acalabrutinib versus ibrutinib in mcl
-
6:52
comparison of btk inhibitors for cll
-
1:04:14
watch drs. mato & shah discuss the latest in btk inhibitors: participate here https://bit.ly/3k6ajg9
-
5:44
acalabrutinib versus ibrutinib for cll
-
13:19
side effects of acalabrutinib vs. ibrutinib in relapsed cll - dr. john seymour ash 2021
-
1:17
dr. susan o'brien compares ibrutinib and chemoimmunotherapy in frontline cll
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
3:25
btk inhibitors in cll: treatment selection
-
1:10
dr. shah on the role of venetoclax in multiple myeloma
-
8:38
acalabrutinib, second-generation btk inhibitor for cll
-
1:33
safety and efficacy of zanubrutinib in patients who are intolerant to ibrutinib and/or acalabrutinib
-
0:22
copy of dr. shah on frontline considerations for the treatment of cml
-
1:23
antibody that defeats all variants of covid-19 found
-
1:26
common side-effects of btk inhibitors (ibrutinib and acalabrutinib) in the treatment of cll